Cornbleet M A, McElwain T J, Kumar P J, Filshie J, Selby P, Carter R L, Hedley D W, Clark M L, Millar J L
Br J Cancer. 1983 Sep;48(3):329-34. doi: 10.1038/bjc.1983.196.
Twenty-eight patients with advanced life-threatening metastatic malignant melanoma were treated with high dose (140-260 mgm-2) intravenous melphalan and autologous bone marrow. Cyclophosphamide "priming" 300 mgm-2 i.v. was given to 19 patients one week previously and this resulted in clinical but not histological evidence of amelioration of gastrointestinal toxicity. In 11 patients (43%) there was evidence of tumour response to treatment and in 2 patients complete remissions were observed. However in most patients, responses were short-lived and no patient lived longer than 17 months from start of treatment or 24 months from first recorded evidence of distant metastatic disease.
28例晚期危及生命的转移性恶性黑色素瘤患者接受了高剂量(140 - 260mgm-2)静脉美法仑和自体骨髓治疗。19例患者在一周前接受了300mgm-2静脉注射环磷酰胺“预处理”,这在临床上减轻了胃肠道毒性,但组织学上无明显改善。11例患者(43%)有肿瘤对治疗有反应的证据,2例患者观察到完全缓解。然而,大多数患者的反应是短暂的,从治疗开始没有患者存活超过17个月,或从首次记录远处转移性疾病证据起超过24个月。